

Amendments to the Specification

Page 1, lines 6-8, please rewrite the paragraph as follows:

This invention relates to the use of a combination of a microtubule-interfering agent and an extracellular signal-regulated kinase (ERK)-mitogen-activated protein (MAP) (hereinafter referred to as " ERK-MAP") kinase cascade inhibitor as an antitumor agent.